for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mediwound Ltd

MDWD.OQ

Latest Trade

2.88USD

Change

-0.00(-0.00%)

Volume

27,896

Today's Range

2.88

 - 

2.97

52 Week Range

2.55

 - 

6.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.88
Open
2.90
Volume
27,896
3M AVG Volume
0.79
Today's High
2.97
Today's Low
2.88
52 Week High
6.09
52 Week Low
2.55
Shares Out (MIL)
27.18
Market Cap (MIL)
78.00
Forward P/E
-13.41
Dividend (Yield %)
--

Next Event

Q3 2019 Mediwound Ltd Earnings Release

Latest Developments

More

Mediwound Q2 Loss Per Share $0.12 Excluding Items

Mediwound Reports Total Revenues For Second Quarter Were $20.7 Million

Mediwound Appoints Boaz Gur-Lavie As Chief Financial Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mediwound Ltd

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Industry

Biotechnology & Drugs

Contact Info

42 Hayarkon Street

+972.8.9324010

http://www.mediwound.com

Executive Leadership

Stephen T. Wills

Chairman of the Board

Sharon Malka

Chief Executive Officer

Eilon Asculai

Vice President, Research & Development

Lior Rosenberg

Chief Medical Officer

Vickie R. Driver

Director

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.860

2017

-0.950

2018

-0.040

2019(E)

-0.108
Price To Earnings (TTM)
6.72
Price To Sales (TTM)
3.76
Price To Book (MRQ)
4.29
Price To Cash Flow (TTM)
6.27
Total Debt To Equity (MRQ)
16.05
LT Debt To Equity (MRQ)
11.12
Return on Investment (TTM)
33.12
Return on Equity (TTM)
26.80

Latest News

Latest News

BRIEF-MediWound Q3 loss per share $0.49

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares

* Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal

BRIEF-MediWound appoints Mr. Stephen T. Wills as chairman

* MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors

BRIEF-MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid

* MediWound Ltd - announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns Source text for Eikon: Further company coverage:

BRIEF-MediWound announces pricing of $22 million public offering of ordinary shares

* MediWound announces pricing of $22 million public offering of ordinary shares

BRIEF-MediWound Ltd files for stock shelf offering; size not disclosed - SEC Filing

* MediWound Ltd files for stock shelf offering; size not disclosed - SEC Filing Source text: [http://bit.ly/2fuY54X] Further company coverage:

BRIEF-MediWound Ltd announces public offering of ordinary shares

* MediWound Ltd. announces public offering of ordinary shares

BRIEF-MediWound successfully completes second cohort of EscharEx phase 2 study

* MediWound successfully completes second cohort of EscharEx phase 2 study

BRIEF-Mediwound reports Q2 loss per share $0.20

* Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S

BRIEF-BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid indications

* BARDA upsizes contract with MediWound and exercises option to fund further NexoBrid® indications

BRIEF-MediWound announces changes to its board of directors

* MediWound announces changes to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Mediwound Q1 loss per share $0.20

* Mediwound ltd - cash use for 2017 is expected to remain within our guidance for 2017 in range of $15.0 million to $17.0 million

BRIEF-Mediwound reports Q4 loss per share $0.09

* Mediwound reports 2016 fourth quarter and full year financial results

BRIEF-MediWound provides update on NexoBrid late-stage study

* MediWound ltd - EMA has endorsed extension of children innovative debridement study (cids) population to include patients age one to 18

BRIEF-Mediwound reports final positive results of phase 2 clinical trial of Escharex

* Mediwound reports final positive results of phase 2 clinical trial of escharex for the debridement of chronic and hard-to-heal wounds

BRIEF-MediWound to submit data package of Escharex to FDA by year-end

* Expects cash use for operating activities for year ended December 31, 2016 to be in range of $17 million to $20 million

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up